Get the Stockscreener App
1.43
7.74%
-0.12
After Hours:
1.43
Codexis Inc stock is traded at $1.43, with a volume of 2.67M.
It is down -7.74% in the last 24 hours and down -12.27% over the past month.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.
See More
Previous Close:
$1.55
Open:
$1.54
24h Volume:
2.67M
Relative Volume:
2.45
Market Cap:
$129.16M
Revenue:
$70.14M
Net Income/Loss:
$-76.24M
P/E Ratio:
-1.2883
EPS:
-1.11
Net Cash Flow:
$-57.06M
1W Performance:
-11.18%
1M Performance:
-12.27%
6M Performance:
-54.02%
1Y Performance:
-69.70%
1-Day Range:
$1.32
$1.545
1-Week Range:
$1.32
$1.885
52-Week Range:
$1.32
$4.765
Codexis Inc Stock (CDXS) Company Profile
Name
Codexis Inc
Sector
Industry
Phone
650-421-8100
Address
200 PENOBSCOT DRIVE, REDWOOD CITY, CA
Compare CDXS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CDXS
Codexis Inc
|
1.43 | 140.00M | 70.14M | -76.24M | -57.06M | -1.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Codexis Inc Stock (CDXS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-24 | Downgrade | The Benchmark Company | Buy → Hold |
| Jun-03-24 | Resumed | Jefferies | Buy |
| May-30-24 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-29-24 | Upgrade | The Benchmark Company | Hold → Buy |
| Nov-07-23 | Downgrade | The Benchmark Company | Buy → Hold |
| Aug-07-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| May-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-31-22 | Resumed | Piper Sandler | Overweight |
| Mar-02-22 | Resumed | Cowen | Outperform |
| Apr-12-21 | Initiated | Piper Sandler | Overweight |
| Mar-01-21 | Initiated | Stifel | Buy |
| Feb-26-21 | Reiterated | H.C. Wainwright | Buy |
| Mar-10-20 | Initiated | The Benchmark Company | Buy |
| Jan-17-19 | Upgrade | First Analysis Sec | Neutral → Outperform |
| May-16-18 | Initiated | Stephens | Overweight |
| Oct-13-17 | Reiterated | H.C. Wainwright | Buy |
| May-31-17 | Initiated | Jefferies | Buy |
| Jan-26-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Jan-04-17 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-06-16 | Initiated | H.C. Wainwright | Buy |
View All
Codexis Inc Stock (CDXS) Latest News
Aberdeen Group plc Expands Stake in Codexis Inc with Significant Share Acquisition - GuruFocus
MACD Signal: Will Codexis Inc benefit from rising consumer demandMarket Performance Recap & Daily Price Action Insights - baoquankhu1.vn
Moving Averages: What are Codexis Incs recent SEC filings showingQuarterly Trade Summary & Growth Oriented Trade Recommendations - baoquankhu1.vn
Aug PreEarnings: What is DYCQRs book value per shareWeekly Investment Report & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Dividend Watch: Is Codexis Inc. stock vulnerable to regulatory risks2025 Sector Review & Daily Momentum Trading Reports - Bộ Nội Vụ
Codexis and Axolabs Partner to Advance Enzymatic RNA Manufacturing - Contract Pharma
How Codexis Inc. stock reacts to Fed rate cutsShare Buyback & Smart Swing Trading Alerts - ulpravda.ru
Codexis CSO Stefan Lutz sells $7949 in shares By Investing.com - Investing.com UK
Codexis CSO Stefan Lutz sells $7949 in shares - Investing.com
Is Codexis Inc. stock safe for conservative investorsJuly 2025 Short Interest & Safe Entry Momentum Tips - ulpravda.ru
Codexis (CDXS) Partners with Axolabs for Innovative RNA Manufact - GuruFocus
New partnership tests greener way to mass-produce RNA medicines - Stock Titan
Codexis Expands Reach of the ECO Synthesis® Manufacturing Platform through a Signed Evaluation Agreement with Axolabs for Oligonucleotide Therapeutics - Yahoo Finance
Q3 2025 Codexis Inc Earnings Call Transcript - GuruFocus
Enzyme Engineering Market Set for Rapid Growth and Trend - openPR.com
Codexis strengthens board with biotech veteran Arthur Levin - MSN
Will Codexis Inc. stock benefit from green energy trendsJuly 2025 Levels & Free Weekly Watchlist of Top Performers - DonanımHaber
Opaleye Management Inc. Reduces Stake in Codexis Inc. - GuruFocus
How Codexis Inc. stock reacts to job market dataPortfolio Profit Report & Expert-Curated Trade Recommendations - Улправда
Opaleye management sells Codexis (CDXS) shares worth $877,846 By Investing.com - Investing.com Nigeria
Opaleye management sells Codexis (CDXS) shares for $1.87 million By Investing.com - Investing.com South Africa
Opaleye management sells Codexis (CDXS) shares for $1.87 million - Investing.com
Codexis : Amendment to Statement of Changes in Beneficial Ownership (Form 4/A) - marketscreener.com
MACD Signal: Why Codexis Inc stock could see breakout soonJuly 2025 Trade Ideas & AI Enhanced Trading Alerts - moha.gov.vn
Specialty Enzymes Market size to cross $12.2 Billion by 2035 | - openPR.com
Perhaps timely catching Codexis Inc (CDXS) would be a good idea - Setenews
Is Codexis Inc. stock supported by strong fundamentalsTrade Risk Report & Verified Technical Signals - Newser
Will Codexis Inc. stock benefit from upcoming earnings reportsMarket Risk Summary & Entry Point Confirmation Alerts - Newser
Codexis' ECO Synthesis® Manufacturing Platform: Transforming RNA Therapeutics - CBS News
Enzyme Engineering Market is Going to Boom: Strategic Insights - openPR.com
A Look at Codexis Inc (CDXS) Shares in the Recent Past Indicates Growth - setenews.com
Major Shareholder Sells Off a Chunk of Codexis Stock! - TipRanks
Codexis (CDXS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Operating cash flow per share of Codexis, Inc. – DUS:4QK - TradingView
Owner Opaleye Management Inc Sells 514,341 ($877.8K) Of Codexis Inc [CDXS] - TradingView
[Form 4] CODEXIS, INC. Insider Trading Activity - Stock Titan
Check out these key findings about Codexis Inc (CDXS) - setenews.com
Codexis Inc (CDXS) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Telemark Asset Management LLC Increases Stock Position in Codexis, Inc. $CDXS - MarketBeat
Dir Wolf Files To Sell 8,952 Of Codexis Inc [CDXS] - TradingView
Can Codexis Inc. stock beat market expectations this quarter2025 Macro Impact & Weekly Watchlist for Consistent Profits - newser.com
Is Codexis Inc. stock attractive for ETFsTrade Analysis Summary & Daily Profit Maximizing Tips - newser.com
Will Codexis Inc. stock outperform tech sector in 2025Quarterly Profit Report & Risk Managed Investment Entry Signals - newser.com
Will Codexis Inc. stock sustain high P E ratiosJuly 2025 Spike Watch & Risk Controlled Daily Trade Plans - newser.com
Codexis Inc Stock (CDXS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.09%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):